Global Myasthenia Gravis Therapies 麻豆原创 Research Report 2023

Publication ID:

PB502239660

Publication Date:

February 8, 2023

Pages:

Publisher:

MRRPB5

Countries:

Global [1]

USD 2,900.00

Pharmaceutical Manufacturing [2]

Healthcare [3]

Pharma & Healthcare [4]

Description:

Myasthenia gravis is a chronic autoimmune neuromuscular disease that causes weakness in the skeletal muscles, which are responsible for breathing and moving parts of the body, including the arms and legs.
Highlights
The global Myasthenia Gravis Therapies market was valued at US$ 1477.7 million in 2022 and is anticipated to reach US$ 2038.7 million by 2029, witnessing a CAGR of 5.5% during the forecast period 2023-2029. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
North American market for Myasthenia Gravis Therapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
Asia-Pacific market for Myasthenia Gravis Therapies is estimated to increase from $ million in 2023 to reach $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The global market for Myasthenia Gravis Therapies in Hospitals and Clinics is estimated to increase from $ million in 2023 to $ million by 2029, at a CAGR of % during the forecast period of 2023 through 2029.
The key global companies of Myasthenia Gravis Therapies include Alexion Pharmaceuticals, Novartis, CSL Behring and Grifols, etc. In 2022, the world's top three vendors accounted for approximately % of the revenue.
Report Scope
This report aims to provide a comprehensive presentation of the global market for Myasthenia Gravis Therapies, with both quantitative and qualitative analysis, to help readers develop business/growth strategies, assess the market competitive situation, analyze their position in the current marketplace, and make informed business decisions regarding Myasthenia Gravis Therapies.
The Myasthenia Gravis Therapies market size, estimations, and forecasts are provided in terms of and revenue ($ millions), considering 2022 as the base year, with history and forecast data for the period from 2018 to 2029. This report segments the global Myasthenia Gravis Therapies market comprehensively. Regional market sizes, concerning products by type, by application, and by players, are also provided.
For a more in-depth understanding of the market, the report provides profiles of the competitive landscape, key competitors, and their respective market ranks. The report also discusses technological trends and new product developments.
The report will help the Myasthenia Gravis Therapies companies, new entrants, and industry chain related companies in this market with information on the revenues for the overall market and the sub-segments across the different segments, by company, by type, by application, and by regions.
By Company
Alexion Pharmaceuticals
Novartis
CSL Behring
Grifols
Segment by Type
Ocular Myasthenia Gravis
Congenital Myasthenia Gravis
Generalized Myasthenia Gravis
Transient Myasthenia Gravis
Others
Segment by Application
Hospitals and Clinics
Diagnostic Centers
Academic and Research Organizations
By Region
North America
United States
Canada
Europe
Germany
France
UK
Italy
Russia
Nordic Countries
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia
Latin America
Mexico
Brazil
Rest of Latin America
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of MEA
Core Chapters
Chapter 1: Introduces the report scope of the report, executive summary of different market segments (by type, application, etc), including the market size of each market segment, future development potential, and so on. It offers a high-level view of the current state of the market and its likely evolution in the short to mid-term, and long term.
Chapter 2: Introduces executive summary of global market size, regional market size, this section also introduces the market dynamics, latest developments of the market, the driving factors and restrictive factors of the market, the challenges and risks faced by companies in the industry, and the analysis of relevant policies in the industry.
Chapter 3: Detailed analysis of Myasthenia Gravis Therapies companies鈥� competitive landscape, revenue market share, latest development plan, merger, and acquisition information, etc.
Chapter 4: Provides the analysis of various market segments by type, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different market segments.
Chapter 5: Provides the analysis of various market segments by application, covering the market size and development potential of each market segment, to help readers find the blue ocean market in different downstream markets.
Chapter 6, 7, 8, 9, 10: North America, Europe, Asia Pacific, Latin America, Middle East and Africa segment by country. It provides a quantitative analysis of the market size and development potential of each region and its main countries and introduces the market development, future development prospects, market space, and capacity of each country in the world.
Chapter 11: Provides profiles of key players, introducing the basic situation of the key companies in the market in detail, including product revenue, gross margin, product introduction, recent development, etc.
Chapter 12: The main points and conclusions of the report.

Please Note - This is an on demand report and will be delivered in 2 business days (48 hours) post payment.

Table Of Contents:

1 Report Overview
1.1 Study Scope
1.2 麻豆原创 Analysis by Type
1.2.1 Global Myasthenia Gravis Therapies 麻豆原创 Size Growth Rate by Type: 2018 VS 2022 VS 2029
1.2.2 Ocular Myasthenia Gravis
1.2.3 Congenital Myasthenia Gravis
1.2.4 Generalized Myasthenia Gravis
1.2.5 Transient Myasthenia Gravis
1.2.6 Others
1.3 麻豆原创 by Application
1.3.1 Global Myasthenia Gravis Therapies 麻豆原创 Growth by Application: 2018 VS 2022 VS 2029
1.3.2 Hospitals and Clinics
1.3.3 Diagnostic Centers
1.3.4 Academic and Research Organizations
1.4 Study Objectives
1.5 Years Considered
1.6 Years Considered
2 Global Growth Trends
2.1 Global Myasthenia Gravis Therapies 麻豆原创 Perspective (2018-2029)
2.2 Myasthenia Gravis Therapies Growth Trends by Region
2.2.1 Global Myasthenia Gravis Therapies 麻豆原创 Size by Region: 2018 VS 2022 VS 2029
2.2.2 Myasthenia Gravis Therapies Historic 麻豆原创 Size by Region (2018-2023)
2.2.3 Myasthenia Gravis Therapies Forecasted 麻豆原创 Size by Region (2024-2029)
2.3 Myasthenia Gravis Therapies 麻豆原创 Dynamics
2.3.1 Myasthenia Gravis Therapies Industry Trends
2.3.2 Myasthenia Gravis Therapies 麻豆原创 Drivers
2.3.3 Myasthenia Gravis Therapies 麻豆原创 Challenges
2.3.4 Myasthenia Gravis Therapies 麻豆原创 Restraints
3 Competition Landscape by Key Players
3.1 Global Top Myasthenia Gravis Therapies Players by Revenue
3.1.1 Global Top Myasthenia Gravis Therapies Players by Revenue (2018-2023)
3.1.2 Global Myasthenia Gravis Therapies Revenue 麻豆原创 Share by Players (2018-2023)
3.2 Global Myasthenia Gravis Therapies 麻豆原创 Share by Company Type (Tier 1, Tier 2, and Tier 3)
3.3 Players Covered: Ranking by Myasthenia Gravis Therapies Revenue
3.4 Global Myasthenia Gravis Therapies 麻豆原创 Concentration Ratio
3.4.1 Global Myasthenia Gravis Therapies 麻豆原创 Concentration Ratio (CR5 and HHI)
3.4.2 Global Top 10 and Top 5 Companies by Myasthenia Gravis Therapies Revenue in 2022
3.5 Myasthenia Gravis Therapies Key Players Head office and Area Served
3.6 Key Players Myasthenia Gravis Therapies Product Solution and Service
3.7 Date of Enter into Myasthenia Gravis Therapies 麻豆原创
3.8 Mergers & Acquisitions, Expansion Plans
4 Myasthenia Gravis Therapies Breakdown Data by Type
4.1 Global Myasthenia Gravis Therapies Historic 麻豆原创 Size by Type (2018-2023)
4.2 Global Myasthenia Gravis Therapies Forecasted 麻豆原创 Size by Type (2024-2029)
5 Myasthenia Gravis Therapies Breakdown Data by Application
5.1 Global Myasthenia Gravis Therapies Historic 麻豆原创 Size by Application (2018-2023)
5.2 Global Myasthenia Gravis Therapies Forecasted 麻豆原创 Size by Application (2024-2029)
6 North America
6.1 North America Myasthenia Gravis Therapies 麻豆原创 Size (2018-2029)
6.2 North America Myasthenia Gravis Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
6.3 North America Myasthenia Gravis Therapies 麻豆原创 Size by Country (2018-2023)
6.4 North America Myasthenia Gravis Therapies 麻豆原创 Size by Country (2024-2029)
6.5 United States
6.6 Canada
7 Europe
7.1 Europe Myasthenia Gravis Therapies 麻豆原创 Size (2018-2029)
7.2 Europe Myasthenia Gravis Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
7.3 Europe Myasthenia Gravis Therapies 麻豆原创 Size by Country (2018-2023)
7.4 Europe Myasthenia Gravis Therapies 麻豆原创 Size by Country (2024-2029)
7.5 Germany
7.6 France
7.7 U.K.
7.8 Italy
7.9 Russia
7.10 Nordic Countries
8 Asia-Pacific
8.1 Asia-Pacific Myasthenia Gravis Therapies 麻豆原创 Size (2018-2029)
8.2 Asia-Pacific Myasthenia Gravis Therapies 麻豆原创 Growth Rate by Region: 2018 VS 2022 VS 2029
8.3 Asia-Pacific Myasthenia Gravis Therapies 麻豆原创 Size by Region (2018-2023)
8.4 Asia-Pacific Myasthenia Gravis Therapies 麻豆原创 Size by Region (2024-2029)
8.5 China
8.6 Japan
8.7 South Korea
8.8 Southeast Asia
8.9 India
8.10 Australia
9 Latin America
9.1 Latin America Myasthenia Gravis Therapies 麻豆原创 Size (2018-2029)
9.2 Latin America Myasthenia Gravis Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
9.3 Latin America Myasthenia Gravis Therapies 麻豆原创 Size by Country (2018-2023)
9.4 Latin America Myasthenia Gravis Therapies 麻豆原创 Size by Country (2024-2029)
9.5 Mexico
9.6 Brazil
10 Middle East & Africa
10.1 Middle East & Africa Myasthenia Gravis Therapies 麻豆原创 Size (2018-2029)
10.2 Middle East & Africa Myasthenia Gravis Therapies 麻豆原创 Growth Rate by Country: 2018 VS 2022 VS 2029
10.3 Middle East & Africa Myasthenia Gravis Therapies 麻豆原创 Size by Country (2018-2023)
10.4 Middle East & Africa Myasthenia Gravis Therapies 麻豆原创 Size by Country (2024-2029)
10.5 Turkey
10.6 Saudi Arabia
10.7 UAE
11 Key Players Profiles
11.1 Alexion Pharmaceuticals
11.1.1 Alexion Pharmaceuticals Company Detail
11.1.2 Alexion Pharmaceuticals Business Overview
11.1.3 Alexion Pharmaceuticals Myasthenia Gravis Therapies Introduction
11.1.4 Alexion Pharmaceuticals Revenue in Myasthenia Gravis Therapies Business (2018-2023)
11.1.5 Alexion Pharmaceuticals Recent Development
11.2 Novartis
11.2.1 Novartis Company Detail
11.2.2 Novartis Business Overview
11.2.3 Novartis Myasthenia Gravis Therapies Introduction
11.2.4 Novartis Revenue in Myasthenia Gravis Therapies Business (2018-2023)
11.2.5 Novartis Recent Development
11.3 CSL Behring
11.3.1 CSL Behring Company Detail
11.3.2 CSL Behring Business Overview
11.3.3 CSL Behring Myasthenia Gravis Therapies Introduction
11.3.4 CSL Behring Revenue in Myasthenia Gravis Therapies Business (2018-2023)
11.3.5 CSL Behring Recent Development
11.4 Grifols
11.4.1 Grifols Company Detail
11.4.2 Grifols Business Overview
11.4.3 Grifols Myasthenia Gravis Therapies Introduction
11.4.4 Grifols Revenue in Myasthenia Gravis Therapies Business (2018-2023)
11.4.5 Grifols Recent Development
12 Analyst's Viewpoints/Conclusions
13 Appendix
13.1 Research Methodology
13.1.1 Methodology/Research Approach
13.1.2 Data Source
13.2 Disclaimer
13.3 Author Details

Companies Mentioned:

Alexion Pharmaceuticals
Novartis
CSL Behring
Grifols

License Types:

Single User License (PDF)

This license allows for use of a publication by one person.
This person may print out a single copy of the publication.
This person can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
This person cannot share the publication (or any information contained therein) with any other person or persons.
Unless a Enterprise License is purchased, a Single User License must be purchased for every person that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Site License (PDF)*

This license allows for use of a publication by all users within one corporate location, e.g. a regional office.
These users may print out a single copy of the publication.
These users can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.
These users cannot share the publication (or any information contained therein) with any other person or persons outside the corporate location for which the publication is purchased.
Unless a Enterprise License is purchased, a Site User License must be purchased for every corporate location by an organization that wishes to use the publication within the same organization.
Customers who infringe these license terms are liable for a Global license fee.

听

Global License (PDF)*

This license allows for use of a publication by unlimited users within the purchasing organization e.g. all employees of a single company.
Each of these people may use the publication on any computer, and may print out the report, but may not share the publication (or any information contained therein) with any other person or persons outside of the organization.
These employees of purchasing organization can include information given in the publication in presentations and internal reports by providing full copyright credit to the publisher.

*If Applicable.